CD8A and cancer: genetically engineered HEK293T cells to stably express the mouse PD‐1 receptor and obtained PD‐1‐receptor‐expressing CMNs, blocking the PD‐1–PD‐L1 immunosuppression axis to enhance cancer immunotherapy and effectively restore depleted CD8+ T cells able to attack cancer cells.